Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1973 2
1974 1
1975 1
1976 5
1977 4
1978 2
1979 4
1980 2
1981 2
1983 2
1986 3
1987 1
1988 5
1989 3
1990 6
1991 7
1993 4
1994 2
1995 4
1996 1
1997 1
1998 2
2000 1
2001 1
2005 3
2008 2
2009 3
2010 4
2011 10
2012 4
2013 4
2014 2
2015 4
2016 6
2017 7
2018 11
2019 22
2020 29
2021 10
Text availability
Article attribute
Article type
Publication date

Search Results

178 results
Results by year
Filters applied: . Clear all
Page 1
Cannabidiol Adverse Effects and Toxicity.
Huestis MA, Solimini R, Pichini S, Pacifici R, Carlier J, Busardò FP. Huestis MA, et al. Curr Neuropharmacol. 2019;17(10):974-989. doi: 10.2174/1570159X17666190603171901. Curr Neuropharmacol. 2019. PMID: 31161980 Free PMC article. Review.
METHODS: Relevant studies reporting CBD's AEs or toxicity were identified from PubMed, Cochrane Central, and EMBASE through January 2019. Studies defining CBD's beneficial effects were included to provide balance in estimating risk/benefit. ...
METHODS: Relevant studies reporting CBD's AEs or toxicity were identified from PubMed, Cochrane Central, and EMBASE through January 2 …
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.
Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S; Cannabidiol in Dravet Syndrome Study Group. Devinsky O, et al. N Engl J Med. 2017 May 25;376(21):2011-2020. doi: 10.1056/NEJMoa1611618. N Engl J Med. 2017. PMID: 28538134 Free article. Clinical Trial.
The patient's overall condition improved by at least one category on the seven-category Caregiver Global Impression of Change scale in 62% of the cannabidiol group as compared with 34% of the placebo group (P=0.02). ...The percentage of patients who became seizure-f …
The patient's overall condition improved by at least one category on the seven-category Caregiver Global Impression of Change scale i …
Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.
Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM; GWPCARE3 Study Group. Devinsky O, et al. N Engl J Med. 2018 May 17;378(20):1888-1897. doi: 10.1056/NEJMoa1714631. N Engl J Med. 2018. PMID: 29768152 Free article. Clinical Trial.
Fourteen patients who received cannabidiol (9%) had elevated liver aminotransferase concentrations. ...Adverse events with cannabidiol included elevated liver aminotransferase concentrations. ...
Fourteen patients who received cannabidiol (9%) had elevated liver aminotransferase concentrations. ...Adverse events with …
Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy.
Samanta D. Samanta D. Pediatr Neurol. 2019 Jul;96:24-29. doi: 10.1016/j.pediatrneurol.2019.03.014. Epub 2019 Mar 22. Pediatr Neurol. 2019. PMID: 31053391 Review.
The exact antiepileptic mechanism of cannabidiol is currently not known, but it modulates a number of endogenous systems and may have a novel anticonvulsant effect. However, it has broad drug-drug interactions with several agents, including inducer and inhibitor of CYP3A4 …
The exact antiepileptic mechanism of cannabidiol is currently not known, but it modulates a number of endogenous systems and may have …
Therapeutic Prospects of Cannabidiol for Alcohol Use Disorder and Alcohol-Related Damages on the Liver and the Brain.
De Ternay J, Naassila M, Nourredine M, Louvet A, Bailly F, Sescousse G, Maurage P, Cottencin O, Carrieri PM, Rolland B. De Ternay J, et al. Front Pharmacol. 2019 May 31;10:627. doi: 10.3389/fphar.2019.00627. eCollection 2019. Front Pharmacol. 2019. PMID: 31214036 Free PMC article. Review.
Background: Cannabidiol (CBD) is a natural component of cannabis that possesses a widespread and complex immunomodulatory, antioxidant, anxiolytic, and antiepileptic properties. ...Any other applications warrant human trials in this population. By reducing alcohol-related …
Background: Cannabidiol (CBD) is a natural component of cannabis that possesses a widespread and complex immunomodulatory, antioxidan …
Cannabidiol attenuates alcohol-induced liver steatosis, metabolic dysregulation, inflammation and neutrophil-mediated injury.
Wang Y, Mukhopadhyay P, Cao Z, Wang H, Feng D, Haskó G, Mechoulam R, Gao B, Pacher P. Wang Y, et al. Sci Rep. 2017 Sep 21;7(1):12064. doi: 10.1038/s41598-017-10924-8. Sci Rep. 2017. PMID: 28935932 Free PMC article.
Cannabidiol (CBD) is a non-psychoactive component of marijuana, which has anti-inflammatory effects. It has also been approved by FDA for various orphan diseases for exploratory trials. Herein, we investigated the effects of CBD on liver injury induced by chronic pl
Cannabidiol (CBD) is a non-psychoactive component of marijuana, which has anti-inflammatory effects. It has also been approved by FDA
A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential.
White CM. White CM. J Clin Pharmacol. 2019 Jul;59(7):923-934. doi: 10.1002/jcph.1387. Epub 2019 Feb 7. J Clin Pharmacol. 2019. PMID: 30730563 Review.
Cannabidiol (CBD) is a highly touted product for many different disorders among the lay press. ...CBD is not risk free, with adverse events (primarily somnolence and gastrointestinal in nature) and drug interactions. CBD has been shown to increase liver function tes
Cannabidiol (CBD) is a highly touted product for many different disorders among the lay press. ...CBD is not risk free, with adverse
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.
Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL, Greenwood S, Morrison G, Sommerville K; GWPCARE1 Part A Study Group. Devinsky O, et al. Neurology. 2018 Apr 3;90(14):e1204-e1211. doi: 10.1212/WNL.0000000000005254. Epub 2018 Mar 14. Neurology. 2018. PMID: 29540584 Free PMC article. Clinical Trial.
OBJECTIVE: To evaluate the safety and preliminary pharmacokinetics of a pharmaceutical formulation of purified cannabidiol (CBD) in children with Dravet syndrome. METHODS: Patients aged 4-10 years were randomized 4:1 to CBD (5, 10, or 20 mg/kg/d) or placebo taken twice dai …
OBJECTIVE: To evaluate the safety and preliminary pharmacokinetics of a pharmaceutical formulation of purified cannabidiol (CBD) in c …
Pharmacokinetics of cannabidiol in dogs.
Samara E, Bialer M, Mechoulam R. Samara E, et al. Drug Metab Dispos. 1988 May-Jun;16(3):469-72. Drug Metab Dispos. 1988. PMID: 2900742
Cannabidiol (CBD) is one of the major nonpsychoactive cannabinoids produced by Cannabis sativa L. ...This clearance value, after its normalization to blood clearance using mathematical equations, approaches the value of the hepatic blood flow; the extraction ratio in the
Cannabidiol (CBD) is one of the major nonpsychoactive cannabinoids produced by Cannabis sativa L. ...This clearance value, after its
A systematic review of cannabidiol dosing in clinical populations.
Millar SA, Stone NL, Bellman ZD, Yates AS, England TJ, O'Sullivan SE. Millar SA, et al. Br J Clin Pharmacol. 2019 Sep;85(9):1888-1900. doi: 10.1111/bcp.14038. Epub 2019 Jul 19. Br J Clin Pharmacol. 2019. PMID: 31222854 Free PMC article.
AIMS: Cannabidiol (CBD) is a cannabis-derived medicinal product with potential application in a wide-variety of contexts; however, its effective dose in different disease states remains unclear. ...There was no signal of positive activity of CBD in small randomised control …
AIMS: Cannabidiol (CBD) is a cannabis-derived medicinal product with potential application in a wide-variety of contexts; however, it …
178 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page